Old Web
English
Sign In
Acemap
>
authorDetail
>
Donna Gallenstein
Donna Gallenstein
Melanoma
Ipilimumab
Pathology
Medicine
Toxicity
4
Papers
490
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab.
2017
Journal of Clinical Oncology
Jeffrey S. Weber
Ragini R. Kudchadkar
Geoffrey T. Gibney
Ronald C. De Conti
Bin Yu
Wenshi Wang
Amod A. Sarnaik
Alberto J Martinez
Jodi Kroeger
Cabell Eysmans
Donna Gallenstein
Xiuhua Zhao
Ann Chen
Show All
Source
Cite
Save
Citations (25)
Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).
2014
Journal of Clinical Oncology
Jeffrey S. Weber
Ragini Kudchadkar
Geoffrey T. Gibney
Bin Yu
PingYan Cheng
Alberto J Martinez
Jodi Kroeger
Donna Gallenstein
Allison Richards
Eric Welsh
Xiuhua Zhao
Xiaotao Qu
Ann Chen
Show All
Source
Cite
Save
Citations (12)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
2013
Journal of Clinical Oncology
Jeffrey S. Weber
Ragini R. Kudchadkar
Bin Yu
Donna Gallenstein
Christine E. Horak
H. David Inzunza
Xiuhua Zhao
Alberto J Martinez
Wenshi Wang
Geoffrey T. Gibney
Jodi Kroeger
Cabell Eysmans
Amod A. Sarnaik
Y. Ann Chen
Show All
Source
Cite
Save
Citations (442)
Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma.
2012
Journal of Clinical Oncology
Ragini R. Kudchadkar
Donna Gallenstein
Alberto J Martinez
Bin Yu
Jeffrey S. Weber
Show All
Source
Cite
Save
Citations (11)
1